Related Experiment Video
Updated: Jun 8, 2026
Cholesterol Efflux Assay
Published on: March 6, 2012
Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines
1Institute of Cellular and System Medicine and Translational Center for Glandular Malignancies, National Health Research Institutes, Zhunan Town, Miaoli County 35053, Taiwan, ROC. cpchuu@nhri.org.tw
Abstract:
Previously, we and other groups reported that liver X receptor (LXR) agonists T0901317, 22(R)-hydroxycholesterol, and 24(S)-hydroxycholesterol suppressed the proliferation of prostate and breast cancer cells. In this study, we report that T0901317 and 22(R)-hydroxycholesterol treatment inhibited the proliferation of different progression stages of LNCaP human prostate cancer cells, as well as different commonly used human cancer cell lines. Cancer cell lines with higher LXRα mRNA expression were more sensitive to 22(R)-hydroxycholesterol-induced inhibition. T0901317 treatment decreased the percentage of the cell population in S-phase and caused G(1) cell cycle arrest. Overexpression of S-phase kinase-associated protein 2 (Skp2) partially blocked the suppressive effect of T0901317 treatment. Modulating LXR signaling is therefore a potential adjuvant therapy for advanced prostate cancer and other types of cancer.
Insights
Liver X receptor (LXR) agonists inhibit prostate and breast cancer cell proliferation. LXR signaling modulation shows potential as an adjuvant therapy for advanced cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Liver X receptor (LXR) agonists, including T0901317 and hydroxycholesterols, have previously demonstrated antiproliferative effects on prostate and breast cancer cells.
- LXR signaling plays a role in cellular processes relevant to cancer development and progression.
Purpose of the Study:
- To investigate the efficacy of LXR agonists T0901317 and 22(R)-hydroxycholesterol in inhibiting the proliferation of various human cancer cell lines, including different stages of LNCaP prostate cancer cells.
- To explore the correlation between LXRα mRNA expression levels and sensitivity to LXR agonist treatment.
- To elucidate the cell cycle effects of T0901317 and identify potential molecular mediators of its action.
Main Methods:
- Treatment of LNCaP and other human cancer cell lines with LXR agonists T0901317 and 22(R)-hydroxycholesterol.
- Assessment of cell proliferation and cell cycle distribution (S-phase and G1 arrest) using flow cytometry.
- Analysis of LXRα mRNA expression levels in different cancer cell lines.
- Investigation of the role of S-phase kinase-associated protein 2 (Skp2) by overexpression studies.
Main Results:
- T0901317 and 22(R)-hydroxycholesterol significantly inhibited the proliferation of LNCaP prostate cancer cells across different progression stages and other tested human cancer cell lines.
- Higher LXRα mRNA expression correlated with increased sensitivity to 22(R)-hydroxycholesterol-induced growth inhibition.
- T0901317 treatment led to a decrease in the S-phase cell population and induced G1 cell cycle arrest.
- Overexpression of Skp2 partially counteracted the antiproliferative effects of T0901317, suggesting its involvement in the LXR agonist's mechanism.
Conclusions:
- LXR agonists T0901317 and 22(R)-hydroxycholesterol demonstrate potent anticancer activity against various human cancer cell lines, including prostate cancer.
- Sensitivity to LXR agonists is influenced by LXRα expression levels.
- LXR agonists exert their antiproliferative effects, in part, by inducing cell cycle arrest.
- Targeting LXR signaling represents a promising strategy for adjuvant therapy in advanced prostate cancer and potentially other malignancies.
